Drugs / HER2 CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04995003 | Dec 2021 → Jun 2028 expected | Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, synovial sarcoma | Baylor College of Medicine | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER2 CAR T cells | “autologous HER2 CAR T cells infused in combination with lymphodepletion chemotherapy and the PD-1 antibody pembrolizumab” NCT04995003 ↗ |
| Action | Deplete | “The investigators have found from previous research that they can put a new gene into T cells that will make them recognize cancer cells and kill them.” NCT04995003 ↗ |
| Modality | Cell therapy | “After this new gene is put into the T cell, the T cell becomes known as a chimeric antigen receptor T cell or CAR T cell.” NCT04995003 ↗ |
| Route | Intravenous | “The fludarabine, cyclophosphamide, and HER2 CAR T cells will be given intravenously” NCT04995003 ↗ |